Management & Board of Directors
Stefan Moese, PhD
CEO
Stefan Moese is an accomplished drug developer with 15 years of experience in US and European biotech focusing on the development of antibody-based therapeutics.
He has worked in all phases of drug development within the areas of ophthalmology, oncology, autoimmunity and neurological diseases.
Most recently in his role as Vice President of Research and Technology at Neurimmune, Stefan is responsible for management of the entire pre-clinical portfolio in collaboration with the CSO up to start of clinical development. He is also in charge of the antibody technologies group and bioinformatics.
Prior to Neurimmune, Stefan led the antibody discovery and automation group at Esbatech and later the global alternative technologies group at Novartis Biologics Center in Basel, CH and Cambridge, US where he continued his work on immunization-based antibody discovery for different disease areas including immuno-oncology, cardiovascular diseases, and ophthalmology. He was also part of the Novartis Biologics Center leadership team and led several global programs with new biologic entities from the preclinical stage up through Phase 1 studies.
In his first Biotech, Stefan was responsible for the initial setup and translation of the founder science into a drug development pipeline for antivirals and oncology applications, ultimately overseeing all biology teams of the company for both sites in Switzerland and the US.
He obtained his Ph.D. in Infection Biology from Max-Planck Institute Berlin, Germany. In addition, he holds a diploma of Chemistry from university of Braunschweig, Germany.
em Prof. Martin E. Schwab, PhD, hon. MD
CSO,
President of the Board
em Prof. of Neuroscience of the University of Zurich and ETH Zurich.
Prof. Martin E. Schwab is a pioneer in spinal cord injury research. He discovered the existence of
“inhibitors of neurite growth” as a cause of the absent regeneration of injured fiber tracts in the central nervous system. An important breakthrough, honored by numerous international prizes, was the demonstration that blocking of the most potent of those nerve fiber growth inhibitors, Nogo-A, led to regeneration and functional repair in adult rats and monkeys after spinal cord injury. These results overthrew the dogma that the adult mammalian central nervous system would be unable to regenerate.
Roger Wetli
CFO
Roger is an experienced tax expert with a MBA (lic.oec.publ., Finance) from the university of Zurich, Switzerland and certified Swiss tax diploma
Roger brings a wealth of experience and expertise in financial management within the biotech sector. Most recently serving as the Senior Director Tax and Finance at Neurimmune AG and Neurimmune Subone AG, Roger’s responsibilities span overseeing financial planning, financial reporting, controlling, treasury and tax strategies aligned with corporate objectives. Armed with an MBA and a strong accounting foundation, Roger merges academic insights with pragmatic financial strategies. His skill set encompasses financial planning, tax optimization, investor relations, financial reporting, controlling, and corporate finance.
Prior to Neurimmune, Roger started his career and held several positions at big four consulting firms, with the focus on international tax planning and structuring. He further gained rich industry experience and expertise whilst working for a leading firm in the specialty chemical industry. He obtained his MBA (lic.oec.publ., Finance) from the university of Zurich, Switzerland and holds a diploma as certified Swiss tax expert.
Dominik Escher, PhD
Member of the Board
Dominik Escher is the former Founder & CEO of ESBATech, a Swiss biotech focusing on next generation antibody fragment drugs.
Alcon acquired ESBATech for USD 589 million in 2009. Subsequently until 2016 Vice President of Alcon Research & Development and at Novartis Member of the Global Ophthalmology Leadership and Global Biologics Leadership. Since 2002, on the Board of the Swiss Biotech Association and President since 2013. PhD Molecular Biologist.
Prof. Roger M. Nitsch, MD
Member of the Board
Prof. Roger M. Nitsch is a neuroscientist with a background in medicine, recognized as a key opinion leader in neurodegenerative disease research, and as a pioneer of disease-modifying therapeutic approaches for neurodegenerative diseases.
The Potamkin prize winner and Member of the German Academy of Sciences directs the Institute for Regenerative Medicine (IREM) at the University of Zurich, Switzerland, and is a co-founder and President of Neurimmune Holding AG.
Jan Grimm, PhD
Member of the Board
Jan Grimm is a neuroscientist with 15 years of experience in US and European biotech focusing on the development of antibody-based therapeutics.
Dr. Grimm is also the CSO and a board member of Neurimmune Holding AG which he co-founded in 2006. Before joining Neurimmune, he led the Alzheimer’s disease research efforts at Rinat Neuroscience in San Francisco that was acquired by Pfizer in 2006. During his tenure at Neurimmune and Rinat, multiple antibody drug candidates for the treatment of Alzheimer’s disease, Parkinson’s disease, Tauopathies and amyotrophic lateral sclerosis advanced from discovery to preclinical and clinical development.